Node NegativePrognostic and Predictive Information for Node-Negative Patients

PrognosticPrognostic for Node-Negative Patients

The Oncotype DX® Breast Recurrence Score™ result is directly associated with the rate of distant recurrence1

Only the Oncotype DX
Breast Recurrence Score
is both prognostic and
predictive of adjuvant
chemotherapy benefit.1,2

A low Breast Recurrence Score result is associated with a lower rate of distant recurrence, while a high Breast Recurrence Score result is associated with a higher rate of distant recurrence.

B-14

NSABP B-14: Prospective analysis of archived tissue from 668 stage I or II patients with estrogen receptor (ER)–positive, node-negative, invasive breast cancer treated with tamoxifen. Twenty-nine percent of patients were < 50 years of age, and 62% had tumors that were ≤ 2.0 cm in size. The 10-year distant recurrence rate for the overall study population was 15%.

The majority of patients (51%) in this study had low Recurrence Score results.1

PredictivePredictive for Node-Negative Patients

Only the Breast Recurrence Score predicts the magnitude of chemotherapy benefit for node-negative patients2

B-20

NSABP B-20: Prospective analysis of archived tissue from 651 patients with ER-positive, node-negative, invasive breast cancer treated with tamoxifen or tamoxifen plus CMF/MF. Approximately 45% of the patients were < 50 years of age, two-thirds of tumors were ≤ 2.0 cm in size, and 20% of tumors were progesterone receptor (PR) negative.

The Breast Recurrence Score predicts the magnitude of chemotherapy benefit across the range of Recurrence Score results, with higher scores corresponding to a greater benefit.

 


Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, sits down with Dr. Christy Russell, Associate Professor of Clinical Oncology and Co-Director at the University of Southern California Norris Lee Breast Center, to discuss examples of when the Breast Recurrence Score made a difference in the breast cancer treatment decisions for patients, both older and younger.

 

REFERENCES
1. Paik et al. N Engl J Med. 2004.
2. Paik et al. J Clin Oncol. 2006.

 

Next: Node Positive: Prognostic and Predictive